Lunit Inc.

About Lunit Inc.

Financials

Dated, source-cited figures. Estimates are marked.

Products by Lunit Inc.

All products by Lunit Inc. reviewed by our AI panel of experts.

LunitAI Healthcare

Cancer-detection AI for radiologists and pathologists, live in 65+ countries

Free7.9/10

How Our Review Panel Scores Lunit Inc.

Six independent reviewer personalities assessed Lunit Inc.'s product on their own terms. They landed within 0.8 points of each other, an unusually strong consensus.

Averaged across 1 reviewed product in our catalog. Scores are out of 10.

Competitive Landscape

Who Lunit Inc. competes with, and how they differ.

Paige.ai7.9/10

Paige focuses exclusively on digital pathology (FDA-cleared whole-slide AI for prostate and breast cancer), competing directly with Lunit SCOPE, while Lunit also covers chest/breast radiology detection that Paige does not address.

1 product reviewed on TopReviewed

PathAI7.9/10

PathAI pairs digital pathology diagnostic algorithms with contract biopharma services for drug-development biomarker studies, a services-heavy revenue model Lunit does not run alongside its SCOPE platform.

1 product reviewed on TopReviewed

Aidoc7.8/10

Aidoc's AI flags time-critical findings across CT and MR studies for hospital radiology workflows, a broader multi-modality triage play than Lunit's chest X-ray- and mammography-focused INSIGHT suite.

1 product reviewed on TopReviewed

Q

Qure.ai7.6/10

Mumbai-based Qure.ai targets the same chest X-ray AI-triage use case as Lunit INSIGHT CXR but leans harder into low-resource and emerging-market health systems (e.g. TB screening) than Lunit's US/EU hospital distribution.

1 product reviewed on TopReviewed

Viz.ai8.0/10

Viz.ai's care-coordination platform triages stroke, pulmonary embolism and aortic disease from CT scans -- an emergency-vascular niche distinct from Lunit's cancer-screening focus, though both sell into the same hospital radiology-AI budget.

1 product reviewed on TopReviewed

Enlitic7.5/10

Enlitic sells a data-standardization and triage layer that normalizes imaging data across a radiology department's existing tools, a more infrastructure-focused approach than Lunit's FDA-cleared, disease-specific detection algorithms.

1 product reviewed on TopReviewed

Company Timeline

Key milestones in Lunit Inc.'s history, with sources.

1. May 22, 2024Acquisition

   Completes Acquisition of Volpara Health Technologies

   Lunit closed its acquisition of New Zealand-based, ASX-listed breast-imaging AI company Volpara Health Technologies for roughly 264.7 billion won ($194M), gaining access to Volpara's installed base of 2,000+ US medical sites.

   kedglobal.com
2. Dec 13, 2023Acquisition

   Signs Scheme Implementation Agreement to Acquire Volpara Health

   Lunit agreed to acquire Volpara Health Technologies for A$1.15 per share in cash, a 47.4% premium to Volpara's prior closing price, via a scheme of arrangement expected to close in Q2 2024.

   prnewswire.com
3. Jul 21, 2022Milestone

   Lists on KOSDAQ, Shares Surge 29.87% on Debut

   Lunit began trading on South Korea's KOSDAQ market at an IPO price of KRW 30,000 per share; shares closed at the upper limit of KRW 40,000, raising roughly KRW 36.4 billion ($28M) for the offering.

   prnewswire.com
4. Nov 25, 2021Funding

   Raises $61M Pre-IPO Round Led by HealthQuest Capital

   Lunit closed a $61M pre-IPO round with HealthQuest Capital ($20M), Casdin Capital, American Cancer Society BrightEdge, Tybourne Capital Management and NSG Ventures, bringing total funding raised to more than $135M.

   prnewswire.com
5. Nov 18, 2021Milestone

   Lunit INSIGHT MMG Wins FDA Clearance for Breast Cancer Detection

   The FDA granted 510(k) clearance to Lunit INSIGHT MMG, the company's AI software for detecting breast cancer on mammography images.

   lunit.io
6. Nov 15, 2021Milestone

   Lunit INSIGHT CXR Triage Wins FDA Clearance for Chest X-ray Emergency Sorting

   The FDA cleared Lunit INSIGHT CXR Triage, a computer-assisted triage tool that flags suspected critical findings such as pneumothorax and pleural effusion on chest X-rays to help prioritize emergency cases.

   lunit.io
7. Jul 19, 2021Funding

   Guardant Health Makes $26M Strategic Investment (Series C Tranche B)

   Precision oncology company Guardant Health invested $26M in Lunit as an extension of its Series C round, paired with a collaboration to combine Guardant's liquid biopsy data with Lunit's SCOPE tissue-analysis AI platform.

   lunit.io
8. Jan 7, 2020Funding

   Raises $26M Series C Led by Shinhan Investment

   Lunit closed a $26M Series C round led by Shinhan Investment with InterVest, IMM Investment, Kakao Ventures and Legend Capital, its largest round to date at the time, to fund global sales of its chest and breast radiology AI.

   lunit.io
9. 2013Founded

   Lunit Founded in Seoul

   Lunit was co-founded in 2013 in Seoul, South Korea, to develop deep-learning AI software for cancer screening in radiology and biomarker analysis in digital pathology.

   prnewswire.com